SUMMARY The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year. Clinical and laboratory assessments were made at four-weekly intervals over a period of 52 weeks. A statistically significant difference (p<O0O5) in mean prednisolone dose was noted between the two groups at the end of 52 weeks, there being a fall in steroid requirement in the azathioprine treated group.
prolonged treatment with corticosteriods and increasing the risk of hypercorticism. The GCA/PMR syndrome is essentially a disease of the elderly, many of whom may also suffer from concomitant diseases, e.g., hypertension, diabetes mellitus, osteoporosis, congestive cardiac failure, which may be adversely affected by long term corticosteroid therapy. For these reasons an alternative to corticosteroid or a steroid-sparing agent for the treatment of PMR/GCA would be invaluable. On the basis of its proved steroid-sparing effect in rheumatoid arthritis3 and its use in other connective tissue disease, azathioprine was selected as a suitable agent for further study. Reports of its efficacy or lack of it in GCA/PMR are mainly anecdotal. There are no reports of satisfactory clinical trials on the role of azathioprine in PMR/GCA.
We report the results of a controlled double blind study over 52 weeks in which we assessed the steroid-sparing effect of azathioprine in the GCA/ PMR syndrome.
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Results
The time and reasons for withdrawal are given in Tables 3 and 4 . Abnormalities in serum alkaline phosphatase, bilirubin, and alanine aminotransferase occurred only in the azathioprine treated group. These occurred either individually or in combination and resolved spontaneously or on reduction of the dose. Two patients receiving azathioprine developed macrocytosis, with mean corpuscular volume > 100 fl at 12 and 40 weeks respectively. This abnormality persisted until the end of the study. No patients were withdrawn because of biochemical or haematological abnormalities. Nausea occurred in both groups of patients but was more severe in the azathioprine treated group. One patient developed severe vomiting and dehydration. Only patients completing a minimum of 36 weeks of the study were included in the statistical analysis.
Results of 10 of 16 patients in the azathioprine group and 12 of 15 in the placebo group were therefore available for analysis. Nine patients in the azathioprine group and 11 patients in the placebo group completed 52 weeks of the study. The steroid requirements of the two groups over the study period are given in Table 5 . The steroid requirement of both groups fell during the course of the study but was more pronounced in the azathioprine treated group. However, with the small numbers involved this difference reached statistical significance only at 52 weeks. Of the nine patients completing 52 weeks of the study, five were able to take 150 mg of azathioprine/day and four 100 mg/day (range 1.5 to 2*7 mg/kg/day). 
